ID: h-16591043d1
Hypothesis

Selective blockade of classical-pathway activation downstream of C1q will reduce synaptotoxic complement amplification while preserving beneficial C1q recognition functions

The most actionable synthesis is that pathogenicity may depend more on conversion of C1q binding into classical-pathway protease activity than on C1q recognition alone.
🧬 C1QA,C1QB,C1QC,C1R,C1S,C4A,C4B,C3🩺 neurodegeneration🎯 Composite 75%💱 $0.60▼19.7%proposed
EvidencePending (0%)📖 8 cit🗣 1 debates 8 support 2 oppose
✓ All Quality Gates Passed
Mechanistic 0.79 (15%) Evidence 0.74 (15%) Novelty 0.58 (12%) Feasibility 0.86 (12%) Impact 0.88 (12%) Druggability 0.91 (10%) Safety 0.62 (8%) Competition 0.63 (6%) Data Avail. 0.77 (5%) Reproducible 0.72 (5%) KG Connect 0.50 (8%) 0.750 composite
🏆 ChallengeSolve: Selective blockade of classical-pathway activation downstream of C1q will$125K →

🧪 Overview

The most actionable synthesis is that pathogenicity may depend more on conversion of C1q binding into classical-pathway protease activity than on C1q recognition alone. In this model, inhibiting C1r/C1s should attenuate C4/C3-mediated synapse loss and neuroinflammation while preserving some homeostatic debris sensing and cargo recognition by C1q.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["C1Q Deficiency<br/>Impaired Clearance of Apoptotic Cells"]
    B["C1QC Assembly<br/>Heterocomplex Formation"]
    C["Synaptic Pruning Dysregulation<br/>Unpruned Connections"]
    D["Microglial Overactivation<br/>Complement Deposition"]
    E["C3b/C4b Deposition<br/>Neuronal Surface"]
    F["Synaptic Loss<br/>Excessive Pruning in AD"]
    G["Long-Term Potentiation<br/>Memory Formation Impaired"]
    H["Cognitive Decline<br/>AD-Related Dementia"]
    A --> B
    B --> C
    B --> D
    C --> F
    D --> E
    E --> F
    F --> G
    G --> H
    style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
    style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

⚖️ Evidence

⚖️ Evidence Matrix8 supports2 contradicts
Supports
C1q/C3-dependent synaptic pruning is established in development, supporting a pathogenic role for downstream complement activation at synapses.
Supports
Early AD-model synapse loss requires classical complement components and microglial CR3, supporting the idea that downstream cascade activation mediates injury.
Supports
Clinical and translational activity around C1q/classical pathway inhibition indicates tractable target biology and therapeutic interest.
Supports
Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer's disease.
Nat Neurosci2023PMID:36747024medium
Supports
Prolonged anesthesia induces neuroinflammation and complement-mediated microglial synaptic elimination involved in neurocognitive dysfunction and anxiety-like behaviors.
BMC Med2023PMID:36600274medium
Supports
Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation.
Cell2016PMID:27114033medium
Supports
A complement-microglial axis drives synapse loss during virus-induced memory impairment.
Nature2016PMID:27337340medium
Supports
The dopamine analogue CA140 alleviates AD pathology, neuroinflammation, and rescues synaptic/cognitive functions by modulating DRD1 signaling or directly binding to Abeta.
J Neuroinflammation2024PMID:39129007medium
Contradicts
It remains unresolved whether C1q recognition is broadly beneficial in the CNS; some harmful effects may arise from C1q binding itself rather than only downstream protease activation.
Contradicts
Blocking C1r/C1s may still impair host defense and immune-complex handling, so CNS benefit may not cleanly separate from systemic risk.
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — C1QA

🧬 PDB 1PK6 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for C1QA,C1QB,C1QC,C1R,C1S,C4A,C4B,C3 from GTEx v10.

Spinal cord cervical c-174.7 Substantia nigra38.2median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for C1QA,C1QB,C1QC,C1R,C1S,C4A,C4B,C3 →

No DepMap CRISPR Chronos data found for C1QA,C1QB,C1QC,C1R,C1S,C4A,C4B,C3.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Falling
7d Momentum
▼ 1.5%
Volatility
Low
0.0074
Events (7d)
3
Price History
▼19.7%

💾 Resource Usage

LLM Tokens
19,754
$0.0593
Total Cost
$0.0593

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF a selective C1r/C1s inhibitor (e.g., C1s-IN-1, 10 mg/kg daily) is administered to APP/PS1 transgenic mice starting at 3 months of age for 8 weeks, THEN the density of excitatory synapses in the hipHippocampal PSD95+ synapse density will increase by at least 20% relative to vehicle control.— no observation —pending0.65
IF human iPSC-derived neurons co-cultured with microglia are treated with a selective C1r/C1s inhibitor (C1s-IN-1, 1 µM) for 48 h prior to exposure to oligomeric Aβ (1 µM), THEN the generation of C3a Supernatant C3a concentration will be at least 30% lower in inhibitor-treated cultures, with no significant change in C1q synaptic coverage.— no observation —pending0.55
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF a selective C1r/C1s inhibitor (e.g., C1s-IN-1, 10 mg/kg daily) is administered to APP/PS1 transgenic mice starting at 3 months of age for 8 weeks, THEN the density of excitatory synapses in the hippocampus (measured by PSD95 immunostaining) will be significantly higher (≥20% increase) compared to
Predicted outcome: Hippocampal PSD95+ synapse density will increase by at least 20% relative to vehicle control.
Falsification: If PSD95+ synapse density in treated mice is not higher than vehicle (p>0.05) or is lower, the hypothesis is disproven.
pendingconf 55%
IF human iPSC-derived neurons co-cultured with microglia are treated with a selective C1r/C1s inhibitor (C1s-IN-1, 1 µM) for 48 h prior to exposure to oligomeric Aβ (1 µM), THEN the generation of C3a in the culture supernatant (measured by ELISA) will be reduced by at least 30% relative to vehicle,
Predicted outcome: Supernatant C3a concentration will be at least 30% lower in inhibitor-treated cultures, with no significant change in C1q synaptic coverage.
Falsification: If C3a levels are not reduced (p>0.05) or if C1q synaptic binding is significantly altered, the hypothesis is disproven.
Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
sourcev1_phase_c_backfill
origin_typedebate_synthesizer
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.